Haleon Plc: 2025 Half Year Results Summary (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing, dated July 31, 2025, announces the half-year results for Haleon Plc (LSE/NYSE: HLN) for the period ending July 31, 2025. Haleon is a global consumer health leader with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The full results statement is referenced but not included in this text.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the referenced "Haleon 2025 Half Year Results" statement available via the provided links.
Material Changes and Dividend Declaration
- Interim Dividend: The Board declared an interim dividend of 2.2 pence per ordinary share for H1 2025.
- Dividend Growth: This represents a 10% increase compared to the interim dividend in 2024.
- Payment Schedule: The dividend is expected to be paid on September 18, 2025, to shareholders on the register as of August 15, 2025.
- Ex-Dividend Dates: August 14, 2025, for ordinary shareholders and August 15, 2025, for ADS holders.
Guidance, Outlook, and Management Commentary
Management stated that, subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings. A recorded results presentation by CEO Brian McNamara and CFO Dawn Allen was scheduled for July 31, 2025, followed by a Q&A session. The filing does not contain specific operational guidance, risk factors, or details on unusual items beyond the dividend announcement.
Investor Verification Checklist
- Verify the full H1 2025 financial performance (revenue, profit, cash flow) in the referenced results statement at the London Stock Exchange or Haleon investor website.
- Confirm the record date of August 15, 2025, for dividend eligibility.
- Review the Dividend Reinvestment Programme (DRIP) election deadline of September 1, 2025, if applicable.
- Access the archived webcast for management's detailed commentary on adjusted earnings and future outlook.